Inflammation and Cancer Immunotherapy Forum Rounded Off
May 11th, Beijing, China
Inflammation and Cancer Immunotherapy Forum was successfully held on May 8th 2015 in Beijing. This event was co-organized by Cancer Hospital Chinese Academy of Medical Sciences (CAMS) and Shenogen Pharma Group. Forum chairman was Dr. Jie He, President of Cancer Hospital CAMS. Jianqiang Cai, vice president of Cancer Hospital CAMS, and Kun Meng, chairman & CEO of Shenogen were co-chair. Distinguished experts in cancer inflammation and immunotherapy field were invited to present cutting-edge research progress and discuss future trends in cancer therapy.
Forum begun as Dr. Cai delivered the opening remarks. The moderators for the first session were Dr. Yan Sun, academician of Chinese Academy of Engineering, and Dr. Genhong Cheng, professor of microbiology in UCLA & director of Center of System Medicine at IBMC, CAMS. There were four high-quality speeches in Session I. Dr. Michael Karin, member of USA National Academy of Sciences, distinguished professor of pharmacology, UCSD as well as Shenogen SAB member, gave a speech on IL-6 role in HCC and colorectal cancer. Dr. Genhong Cheng talked about innate immunity against cancers. Dr. Chunfeng Qu, professor of Cancer Hospital CAMS, shared research on host immunity, chronic HBV infections for prevention of primary liver cancer. Dr. Xuchao Zhang, associate professor of Guangdong General Hospital, talked about biomarker design and clinical trial in China.
The second session was moderated by two young PIs elected to the Recruitment Program of Global Youth Experts, Dr. Yuchen Jiao and Dr. Chen Wu, from Cancer Hospital CAMS. Dr. Xiaoyan Qiu, professor of Peking University, gave a talk on cancer immune suppression microenvironment and cancer immune escape. Dr. Kang Li, Head of Biologics at Beigene, shared his perspectives on cancer immunotherapy as a new era of war on cancer. At the end of the forum, Dr. Kun Meng addressed closing remarks with Thanks, Target and Therapy to show gratitude to all the guests and confidence in future cancer treatment.
Nowadays, the molecular mechanism of cancer pathogenesis is being discovered further and immunotherapy is becoming one of the hottest areas in cancer therapy. Over a hundred participants from research institutes, hospitals as well as pharmaceutical companies attended and highly praised the forum.
About Shenogen
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.